Literature DB >> 3629585

The influence of chirality on the delayed neuropathic potential of some organophosphorus esters: neuropathic and prophylactic effects of stereoisomeric esters of ethyl phenylphosphonic acid (EPN oxon and EPN) correlate with quantities of aged and unaged neuropathy target esterase in vivo.

M K Johnson, D J Read.   

Abstract

Organophosphate-induced delayed polyneuropathy (OPIDP) is thought to result from organophosphorylation of neuropathy target esterase (NTE), followed by an "aging" of the phosphorylated NTE. Prophylactic against OPIDP should thus be achieved by production of an inhibited but "nonaging" NTE. Resolved stereoisomers of ethyl phenylphosphonic acid esters produce two forms of inhibited NTE; in vitro one form ages rapidly and the other only negligibly. The present study examined the in vivo effects of two preparations of incompletely resolved isomers of EPN oxon (ethyl 4-nitrophenyl phenylphosphonate) and its thionate on adult hen brain and spinal cord NTE and the relationship of inhibition and aging to the development of OPIDP. Single doses of the L-(-)-isomers (Preparation A, 7:3 proportion of isomers, or Preparation B, 9:1) caused severe neuropathy after doses which produced 70% aged inhibited NTE and mild effects after 50-60%. Single doses of the D-(+)-isomers produced either equal amounts of aged and unaged inhibited NTE (Preparation A) or predominantly unaged (Preparation B): the amount of aged was never more than 50% and no clinical OPIDP occurred. Doses of D-(+) which produced 50% unaged inhibited NTE were protective: challenge with the highly neuropathic phenyl saligenin cyclic phosphate did not cause OPIDP. All effects are consistent with the two-stage initiation process which requires both inhibition of NTE and subsequent modification of the protein by an "aging" process. Previously reported neuropathic effects of D-(+)-EPN probably reflect a substantial proportion of L-(-)-isomer present in the test material. Neuropathic studies with chiral OP esters should consider the possibility of production of protective unaged inhibited NTE in test animals.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3629585     DOI: 10.1016/0041-008x(87)90311-5

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  8 in total

1.  Anomalous biochemical responses in tests of the delayed neuropathic potential of methamidophos (O,S-dimethyl phosphorothioamidate), its resolved isomers and of some higher O-alkyl homologues.

Authors:  M K Johnson; E Vilanova; D J Read
Journal:  Arch Toxicol       Date:  1991       Impact factor: 5.153

Review 2.  Neuropathy target esterase.

Authors:  P Glynn
Journal:  Biochem J       Date:  1999-12-15       Impact factor: 3.857

Review 3.  Prophylaxis and the mechanism for the initiation of organophosphorous compound-induced delayed neurotoxicity.

Authors:  C D Carrington
Journal:  Arch Toxicol       Date:  1989       Impact factor: 5.153

4.  Interaction of methamidophos with hen and human acetylcholinesterase and neuropathy target esterase.

Authors:  M Bertolazzi; S Caroldi; A Moretto; M Lotti
Journal:  Arch Toxicol       Date:  1991       Impact factor: 5.153

5.  Triphenylphosphite neuropathy in hens.

Authors:  F Fioroni; A Moretto; M Lotti
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

6.  Organophosphate polyneuropathy and neuropathy target esterase: studies with methamidophos and its resolved optical isomers.

Authors:  M Lotti; A Moretto; M Bertolazzi; M Peraica; F Fioroni
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

7.  Neuropathy target esterase (NTE/PNPLA6) and organophosphorus compound-induced delayed neurotoxicity (OPIDN).

Authors:  Rudy J Richardson; John K Fink; Paul Glynn; Robert B Hufnagel; Galina F Makhaeva; Sanjeeva J Wijeyesakere
Journal:  Adv Neurotoxicol       Date:  2020-03-03

8.  Analysis of the neurotoxic effects of neuropathic organophosphorus compounds in adult zebrafish.

Authors:  Melissa Faria; Inmaculada Fuertes; Eva Prats; Jose Luis Abad; Francesc Padrós; Cristian Gomez-Canela; Josefina Casas; Jorge Estevez; Eugenio Vilanova; Benjamin Piña; Demetrio Raldúa
Journal:  Sci Rep       Date:  2018-03-19       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.